These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 31115964)

  • 1. Cardiovascular outcomes of vildagliptin in patients with type 2 diabetes mellitus after acute coronary syndrome or acute ischemic stroke.
    Chen DY; Li YR; Mao CT; Tseng CN; Hsieh IC; Hung MJ; Chu PH; Wang CH; Wen MS; Cherng WJ; Chen TH
    J Diabetes Investig; 2020 Jan; 11(1):110-124. PubMed ID: 31115964
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Linagliptin and cardiovascular outcomes in type 2 diabetes after acute coronary syndrome or acute ischemic stroke.
    Li YR; Tsai SS; Chen DY; Chen ST; Sun JH; Chang HY; Liou MJ; Chen TH
    Cardiovasc Diabetol; 2018 Jan; 17(1):2. PubMed ID: 29301579
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sitagliptin and cardiovascular outcomes in diabetic patients with chronic kidney disease and acute myocardial infarction: A nationwide cohort study.
    Chen DY; Wang SH; Mao CT; Tsai ML; Lin YS; Chou CC; Wen MS; Wang CC; Hsieh IC; Hung KC; Chen TH
    Int J Cardiol; 2015 Feb; 181():200-6. PubMed ID: 25528312
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early and Chronic Dipeptidyl-Peptidase-IV Inhibition and Cardiovascular Events in Patients With Type 2 Diabetes Mellitus After an Acute Coronary Syndrome: A Landmark Analysis of the EXAMINE Trial.
    Sharma A; Cannon CP; White WB; Liu Y; Bakris GL; Cushman WC; Zannad F
    J Am Heart Assoc; 2018 May; 7(11):. PubMed ID: 29769203
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dipeptidyl peptidase-4 inhibitors and cardiovascular risks in patients with pre-existing heart failure.
    Ou SM; Chen HT; Kuo SC; Chen TJ; Shih CJ; Chen YT
    Heart; 2017 Mar; 103(6):414-420. PubMed ID: 27647170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Similar Cardiovascular Outcomes Between Insulin Detemir and Insulin Glargine In Type 2 Diabetic Patients With Extremely Atherosclerotic Cardiovascular Disease Risks.
    Chen TH; Wang CC; Liu CH; Hsiao CC; Chen ST; Liu FH; Ho MY; Li YR
    Endocr Pract; 2020 Aug; 26(8):818-829. PubMed ID: 33471673
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EXamination of cArdiovascular outcoMes with alogliptIN versus standard of carE in patients with type 2 diabetes mellitus and acute coronary syndrome (EXAMINE): a cardiovascular safety study of the dipeptidyl peptidase 4 inhibitor alogliptin in patients with type 2 diabetes with acute coronary syndrome.
    White WB; Bakris GL; Bergenstal RM; Cannon CP; Cushman WC; Fleck P; Heller S; Mehta C; Nissen SE; Perez A; Wilson C; Zannad F
    Am Heart J; 2011 Oct; 162(4):620-626.e1. PubMed ID: 21982652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular Outcomes of Dipeptidyl Peptidase-4 Inhibitors in Elderly Patients With Type 2 Diabetes: A Nationwide Study.
    Shih CJ; Chen HT; Kuo SC; Ou SM; Chen YT
    J Am Med Dir Assoc; 2016 Jan; 17(1):59-64. PubMed ID: 26612484
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus.
    Hemmingsen B; Sonne DP; Metzendorf MI; Richter B
    Cochrane Database Syst Rev; 2017 May; 5(5):CD012204. PubMed ID: 28489279
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular Outcomes of Sitagliptin in Type 2 Diabetic Patients with Acute Myocardial Infarction, a Population-Based Cohort Study in Taiwan.
    Wang SH; Chen DY; Lin YS; Mao CT; Tsai ML; Hsieh MJ; Chou CC; Wen MS; Wang CC; Hsieh IC; Hung KC; Chen TH
    PLoS One; 2015; 10(6):e0131122. PubMed ID: 26115092
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular and heart failure safety profile of vildagliptin: a meta-analysis of 17 000 patients.
    McInnes G; Evans M; Del Prato S; Stumvoll M; Schweizer A; Lukashevich V; Shao Q; Kothny W
    Diabetes Obes Metab; 2015 Nov; 17(11):1085-92. PubMed ID: 26250051
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Baseline adiponectin concentration and clinical outcomes among patients with diabetes and recent acute coronary syndrome in the EXAMINE trial.
    Bergmark BA; Cannon CP; White WB; Jarolim P; Liu Y; Bonaca MP; Zannad F; Morrow DA
    Diabetes Obes Metab; 2017 Jul; 19(7):962-969. PubMed ID: 28195387
    [TBL] [Abstract][Full Text] [Related]  

  • 13. No increased risk of hospitalization for heart failure for patients treated with dipeptidyl peptidase-4 inhibitors in Taiwan.
    Chang CH; Chang YC; Lin JW; Caffrey JL; Wu LC; Lai MS; Chuang LM
    Int J Cardiol; 2016 Oct; 220():14-20. PubMed ID: 27389437
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Total cardiovascular events analysis of the EXAMINE trial in patients with type 2 diabetes and recent acute coronary syndrome.
    Cavender MA; White WB; Liu Y; Massaro JM; Bergenstal RM; Mehta CR; Zannad F; Heller S; Cushman WC; Cannon CP
    Clin Cardiol; 2018 Aug; 41(8):1022-1027. PubMed ID: 29652078
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dipeptidyl Peptidase-4 Inhibitors and Risk of Heart Failure in Patients With Type 2 Diabetes Mellitus: A Population-Based Cohort Study.
    Kim YG; Yoon D; Park S; Han SJ; Kim DJ; Lee KW; Park RW; Kim HJ
    Circ Heart Fail; 2017 Sep; 10(9):. PubMed ID: 28899989
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardioprotective effects of dipeptidyl peptidase-4 inhibitors versus sulfonylureas in addition to metformin: A nationwide cohort study of patients with type 2 diabetes.
    Wang J; Wu HY; Chien KL
    Diabetes Metab; 2022 May; 48(3):101299. PubMed ID: 34728339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Major adverse cardiovascular and limb events in patients with diabetes and concomitant peripheral artery disease treated with sodium glucose cotransporter 2 inhibitor versus dipeptidyl peptidase-4 inhibitor.
    Lee HF; Chen SW; Liu JR; Li PR; Wu LS; Chang SH; Yeh YH; Kuo CT; Chan YH; See LC
    Cardiovasc Diabetol; 2020 Sep; 19(1):160. PubMed ID: 32998736
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects on Clinical Outcomes of Adding Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas to Metformin Therapy in Patients With Type 2 Diabetes Mellitus.
    Ou SM; Shih CJ; Chao PW; Chu H; Kuo SC; Lee YJ; Wang SJ; Yang CY; Lin CC; Chen TJ; Tarng DC; Li SY; Chen YT
    Ann Intern Med; 2015 Nov; 163(9):663-72. PubMed ID: 26457538
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vildagliptin vs. insulin treatment alone in diabetic acute coronary syndrome patients.
    Dobrecky-Mery I; Sommer A
    Coron Artery Dis; 2021 Jan; 32(1):4-9. PubMed ID: 32310854
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction.
    Furtado RHM; Bonaca MP; Raz I; Zelniker TA; Mosenzon O; Cahn A; Kuder J; Murphy SA; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Ruff CT; Nicolau JC; Gause-Nilsson IAM; Fredriksson M; Langkilde AM; Sabatine MS; Wiviott SD
    Circulation; 2019 May; 139(22):2516-2527. PubMed ID: 30882239
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.